Neostigmine is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. All registered phases are Not applicable. The sponsor with the most trials is The Fourth Affiliated Hospital of Zhejiang University School of Medicine (1). The most-studied condition is Neuromuscular Blockade.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
The Clinical Effect of Sugammadex Sodium (Domestic) for Antagonizing Neuromuscular Blockade After Thoracic Surgery
NCT06334562 · ClinicalTrials.gov ↗ · Neuromuscular Blockade
|
Not applicable | Recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | China |
|
Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function
NCT07309393 · ClinicalTrials.gov ↗ · Residual Neuromuscular Block
|
Not applicable | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 1 |
| Shanghai Pulmonary Hospital, Shanghai, China | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Neostigmine as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The Fourth Affiliated Hospital of Zhejiang University School of Medicine (1) and Shanghai Pulmonary Hospital, Shanghai, China (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Neostigmine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Neostigmine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Neostigmine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.